FY2026 Earnings Estimate for COYA Issued By Chardan Capital

Coya Therapeutics, Inc. (NASDAQ:COYA) – Equities researchers at Chardan Capital issued their FY2026 EPS estimates for shares of Coya Therapeutics in a note issued to investors on Wednesday, May 14th. Chardan Capital analyst K. Nakae forecasts that the company will earn ($1.93) per share for the year. Chardan Capital currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share.

Separately, D. Boral Capital restated a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a research note on Tuesday, April 22nd.

Coya Therapeutics Stock Performance

NASDAQ:COYA opened at $5.93 on Friday. The firm has a market cap of $99.18 million, a P/E ratio of -9.12 and a beta of 0.49. Coya Therapeutics has a fifty-two week low of $4.65 and a fifty-two week high of $10.24. The firm has a 50-day simple moving average of $6.05 and a two-hundred day simple moving average of $6.18.

Coya Therapeutics (NASDAQ:COYA) last released its earnings results on Tuesday, May 13th. The company reported ($0.44) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.44). The business had revenue of $257.88 million during the quarter, compared to analysts’ expectations of $2.63 million.

Institutional Trading of Coya Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of COYA. Northern Trust Corp boosted its holdings in shares of Coya Therapeutics by 12.2% during the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock valued at $164,000 after acquiring an additional 3,099 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Coya Therapeutics by 1,005.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock valued at $30,000 after acquiring an additional 4,777 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Coya Therapeutics by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 150,576 shares of the company’s stock valued at $863,000 after acquiring an additional 8,267 shares during the last quarter. Charles Schwab Investment Management Inc. purchased a new stake in shares of Coya Therapeutics during the 1st quarter valued at about $65,000. Finally, XTX Topco Ltd purchased a new stake in shares of Coya Therapeutics during the 4th quarter valued at about $59,000. 39.75% of the stock is currently owned by institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.